

In the Specification:

At page 1, immediately after the title please insert the following paragraph:

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the U.S. National Stage filing of International Application Serial No. PCT/GB2003/003758 filed August 21, 2003, which claims priority to GB 0219524.6 filed August 21, 2002, each of which is incorporated herein by reference in its entirety.--

At page 1, immediately prior to line 4, please insert the following heading:

--FIELD OF THE INVENTION--

At page 1, immediately prior to line 8, please insert the following heading:

--BACKGROUND OF THE INVENTION--

At page 3, immediately prior to line 1, please insert the following heading:

--SUMMARY OF THE INVENTION--

At page 3, immediately prior to line 9, please insert the following:

--BRIEF DESCRIPTION OF THE DRAWINGS--

The invention will now be further described by way of reference to the following Figures which are provided for the purposes of illustration only and are not to be construed as being limiting on the invention. Reference is made to a number of Figures in which:

FIGURE 1 shows the effects of antibody on PNTla cell proliferation.

FIGURE 2 shows the effects of antibody on aortic smooth muscle cell proliferation by assaying uptake of tritiated thymidine.

FIGURE 3 shows the results of cell adhesion assay of MCF-7 cells on extracellular matrix protein.

FIGURE 4 shows the results of chemoinvasion assay of MCF-7 cells on extracellular matrix protein.

FIGURE 5 shows results of Western blots in assay of expression of integrins alpha-3 and beta-1 in breast cancer cells.

FIGURE 6 shows antibody 6313/G2 stimulation of calcium responses in MCF-7 cells.

FIGURE 7 shows antibody 6313/G2 stimulation of calcium responses in RASMC.

FIGURE 8 shows a schematic diagram of the actions of angiotensin-II, the site of the monoclonal antibody activation and the site of monoclonal antibody block.

FIGURE 9 shows sequence homologies for the N-terminal sequences of angiotensin-11 type-1 receptor from different species, where "X" denotes a missing residue, and "-" denotes an identical residue.

DESCRIPTION OF EMBODIMENTS--

Please amend the paragraph beginning at page 14, line 23 of the specification as follows:

--The invention will now be further described by way of reference to the following Examples and Figures which are provided for the purposes of illustration only and are not to be construed as being limiting on the invention. Reference is made to a number of Figures in which:--

Please delete the paragraph beginning at page 14, line 28 of the specification.

Please delete the paragraph beginning at page 14, line 30 of the specification.

Please delete the paragraph beginning at page 15, line 1 of the specification.

Please delete the paragraph beginning at page 15, line 4 of the specification.

Please delete the paragraph beginning at page 15, line 7 of the specification.

Please delete the paragraph beginning at page 15, line 10 of the specification.

Please delete the paragraph beginning at page 15, line 13 of the specification.

Please delete the paragraph beginning at page 15, line 16 of the specification.

Please delete the paragraph beginning at page 15, line 20 of the specification.